MNTA – Confirmed on today’s NVS CC that Sandoz is seriously considering a generic-Lovenox filing in the EU. Executives are studying the EMEA guidance docs on this subject before deciding how to proceed.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”